Company: CSCIF
Filing Date: 2025-04-09
Form Type: 20-F
Source: 0001641172-25-003456
Chunk: 10

Company: COSCIENS Biopharma Inc.
Filing Date: 2025-04-09
Form: 20-F
Item: Item 3
Chunk 10
---
.
 
We have opted to sunset certain previously initiated significant early-stage pre-clinical programs. 
 
We have made the strategic decision to discontinue all investment in our previously initiated ALS, DC-PTH and AIM Biologicals programs. As a result, we will not realize any potential benefits, including product revenues, that may have been realized by instead continuing to pursue such programs, which may negatively impact our business, financial condition and/or results of operations. In addition, there can be no guarantee that our change in strategic direction will lead to the results desired or anticipated by management, and any such failure may also negatively impact our business, financial condition and/or results of operations.
 
We may be unable to accelerate the planned scale-up of PGX Technology towards commercial levels.
 
In 2023, we commenced a collaboration with Austria-based NATEX Prozesstechnologie GesmbH to accelerate the scale-up of PGX Technology at our Edmonton facility and at the Natex Termitz facility. The scale up of our PGX-50L unit located at our Edmonton facility was completed in Q4, 2024, whilst the completion of the PGX100L at the Natex Termitz facility is expected to be completed by Q2, 2025. In addition, we previously announced our goal to commercialize our yeast beta glucan (YBG) product in capsule form as an immune booster in Q2 2025, as part of the ongoing PGX scale up project in Edmonton. Any delay in completing, or any failure to complete, either the Edmonton or Natex Termitz facility could impact our business relationships and could have an overall material adverse effect on our business, financial condition and/or results of operations. Similarly, any delay in completing the scale-up project, or any failure to complete the scale-up project entirely, could impact our business relationships and could have an overall material adverse effect on our business, financial condition and/or results of operations. In addition, even if we are successful in scaling up our PGX Technology to commercial levels, there can be no guarantee that doing so will have the results desired or expected by management.
 
We may require significant additional financing, and we may not have access to sufficient capital.
 
We may require significant additional capital to fund our commercialization efforts and may require additional capital to pursue planned activities, including clinical trials, regulatory approvals, expansion of product offerings and related marketing and product launch costs. Although we believe that our existing cash on hand will be sufficient to fund our anticipated operating and capital